Parallel Advisors LLC Has $786,000 Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Parallel Advisors LLC lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 16.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,104 shares of the biopharmaceutical company’s stock after selling 220 shares during the period. Parallel Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $786,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of REGN. State Street Corp boosted its stake in Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after acquiring an additional 61,277 shares during the last quarter. Amundi boosted its stake in Regeneron Pharmaceuticals by 45.8% in the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock valued at $1,138,074,000 after acquiring an additional 487,489 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 695,799 shares of the biopharmaceutical company’s stock valued at $495,639,000 after acquiring an additional 22,538 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its stake in Regeneron Pharmaceuticals by 0.4% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 302,616 shares of the biopharmaceutical company’s stock valued at $215,562,000 after acquiring an additional 1,108 shares during the last quarter. Finally, Candriam S.C.A. boosted its stake in Regeneron Pharmaceuticals by 3.6% in the fourth quarter. Candriam S.C.A. now owns 261,498 shares of the biopharmaceutical company’s stock valued at $186,273,000 after acquiring an additional 8,973 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the topic of a number of recent research reports. Robert W. Baird reduced their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 5th. Bernstein Bank reduced their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Leerink Partners raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. UBS Group cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Finally, Piper Sandler reduced their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Stock Up 1.1 %

Shares of REGN stock opened at $672.36 on Thursday. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The firm’s fifty day moving average price is $691.62 and its two-hundred day moving average price is $822.93. The firm has a market capitalization of $73.51 billion, a P/E ratio of 17.56, a PEG ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company’s revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business earned $11.86 EPS. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.52%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.